JAMA Network Home
Sign In
Research Letter

Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer

JAMA Network Open 10.1001/jamanetworkopen.2026.34330

September 17, 2026 at 11:00 AM EDT

Read the full article

This comparative effectiveness research examines the association between neoadjuvant chemotherapy adoption by US cancer programs and 10-year survival among patients with advanced ovarian cancer.

Corresponding Author: Alexander Melamed, MD, MPH, Department of Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (alexander.melamed@mgh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.34330?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091726

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks